CClinicalTrials.gg
Sign In
CompletedNCT03752333CUPemUpdated May 4, 2026Results posted

Trial of Pembrolizumab in Cancer of Unknown Primary

A Phase 2 interventional study of Pembrolizumab in Cancer of Unknown Primary Site, sponsored by Imperial College London. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Imperial College London · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Abbreviated Title : CUPem Clinical Indication : A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary Trial Type : Single Arm, non-randomised; Two-stage; Hypothesis generating Type of control : None Route of administration : IV Trial Blinding : N/A

Treatment Groups :Two cohorts:

(i) First Cohort: One or more lines of prior therapy (ii) Second Cohort: First Line untreated CUP patients Number of trial subjects : i) First Cohort: 20 ii) Second Cohort: 57 Eligibility Criteria : The Eligibility Criteria are the same as used in the A trial of chemotherapy for cancer of unknown primary (CUP-ONE) trial in the United Kingdom (UK), please see below.

  • Histologically confirmation of a diagnosis of CUP, with imaging and all diagnostic investigations confirmed as CUP within a CUP Multidisciplinary Team (MDT).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Patients must have disease that is not amenable to potentially curative options such as resection or radical radiotherapy
  • If patient's disease presentation precludes tumour biopsy (inaccessible or biopsy thought not to be in the patient's best interest), the patient is not study eligible.

Estimated recruitment period : 2 years Estimated duration of trial : 3.9 years including set up, recruitment, follow up and close down.

Duration of Participation : Cohort 1 = 6-8 months; Cohort 2 = 8-18 months Estimated average length of treatment per patient =6 months

Read the detailed description

An open label, non-randomised, single arm, sequential phase (two sequential cohorts) study, evaluating the preliminary efficacy of Pembrolizumab in Cancer of unknown Primary (CUP).

Cohort 1:

Cohort 1 will enrol a maximum of 20 patients, who have had at least one prior line / regimen of chemotherapy (at least 2 cycles) appropriate for CUP and who have not had a RECIST response to first-line chemotherapy, or are progressing after an initial response, or are treatment intolerant to first-line chemotherapy, due to unacceptable toxicity.

As soon as there has been one documented response in cohort 1, the study then proceeds to enrol cohort 2 in parallel. Cohort 2 will not be initiated, if have been no cohort 1 (0/20) patients who have benefitted and 20 cohort 1 patients have completed at least 12 weeks of therapy. Benefit for this study is defined as either a RECIST or irRECIST response; stable disease for a minimum of 12 weeks. This allows a go / no-go decision to proceed/ not proceed to enrolling cohort 2 by the trial management group

Cohort 2:

Cohort 2 will enrol a maximum of 57 patients who are chemo-naïve (first-line setting) for CUP*, with a PS 0-2. Benefit for this study is defined as either a RECIST or irRECIST response or stable disease at 12 weeks.

*Previous chemotherapy for other cancers is allowed

For both cohorts, patients will undergo screening procedures during a standard 28-days time window from initiation of the study, under standard Good Clinical Practice (GCP) and informed consent. Restaging will be performed by computerized tomography using ir-RECIST criteria at 3 months from initiation of systemic treatment and on an 8 weekly basis thereafter until radiological proven disease progression or intolerance or patient choice.

The EORTC Quality of Life Questionnaire (QLQ-C30) questionnaire (to assess the quality of life) will be done at baseline after 3 months and then at discontinuation of study treatment.

Correlative translational study samples (blood) and tissue (used for histological confirmation and to document Programmed Death-Ligand 1 (PD-L1) expression) will be collected at baseline, and blood and serum samples monthly (after an informed optional consent and banked for retrospective immune-modulating and other biomarkers for future research and analysis).

02

Conditions studied

  • Cancer of Unknown Primary Site

Keywords

  • Carcinoma, Oncology, Cancer biology
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Be willing and able to provide written informed consent/assent for the trial.
  2. Be 18 years of age on day of signing informed consent.
  3. Have measurable disease based on RECIST 1.1
  4. Be willing to provide consent for archival tumour (in the form of formalin fixed paraffin embedded (FFPE) block) or fresh tumour material (if judged technically feasible by radiologist is mandatory for diagnosis and biomarker analysis.
  5. Have a performance status of 0-2 on the ECOG Performance Scale.

  6. Cohort 1 - have had at least one prior line / regimen of chemotherapy appropriate for CUP (at least 2 cycles), have not had a RECIST response to first-line chemotherapy, or are progressing after an initial response, or are treatment intolerant to first-line chemotherapy, due to unacceptable toxicity.

    Cohort 2 - be chemo-naive for CUP*

    *Previous chemotherapy for other cancers is allowed

  7. Adequate organ and bone marrow function (all screening tests should be performed within 10 days of treatment initiation):

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    2. Platelets ≥ 100 x 109/L
    3. Haemoglobin ≥ 9 g/dL (≥90 g/L) without transfusion or Erythropoietin (EPO) dependency (within 7 days of assessment)

    4. Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN) or Creatinine clearance* ≥ 60 mL/min for patients with creatinine levels > 1.5 x ULN

      * Creatinine clearance should be calculated per institutional standard

    5. Serum total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 ULN
    6. Aspartate aminotransferase [AST] ≤ 2.5 x ULN (\< 5 x ULN if liver metastases are present)
    7. Alanine aminotransferase [ALT]) ≤ 2.5 x ULN (\< 5 x ULN if liver metastases are present)
    8. Albumin ≥ 2.5g/dL
    9. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN (unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
    10. Activated Partial Thromboplastin Time (APTT) ≤1.5 X ULN (unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
  8. Female subject of childbearing potential should have a mandatory negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.

  9. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 6.9.2 - Contraception, for the course of the study through 120 days after the last dose of study medication.

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

  10. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 6.9.2 - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

Exclusion criteria

Exclusion Criteria:

  1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  3. Has a known history of active Bacillus Tuberculosis (TB)
  4. Hypersensitivity to pembrolizumab or any of its excipients.
  5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

  6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.

    • Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
    • Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
  9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  11. Has an active infection requiring systemic therapy.
  12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
  16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., Hepatitis-C Virus (HCV) RNA [qualitative] is detected).
  18. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Pembrolizumab

    All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).

    Drug: Pembrolizumab

Interventions

  • DrugPembrolizumab

    Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies. The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.

    Also known as: Keytruda

05

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by RECIST Criteria v1.1 in the Second-line & First-line Setting.

    The Response Evaluation Criteria in Solid Tumours (RECIST) criteria v1.1. classifies response based on the assessment of target and non-target lesions on CT scans as: Complete Response (CR): requires all of: * disappearance of all target and non-target lesions * pathological lymph nodes must have reduced to \<10 mm in short axis * no new lesions Partial Response (PR): requires all of: * at least 30% decrease in sum of diameters (SOD) of target lesions compared to baseline sum diameters * non-progressive disease of non-target lesions * no new lesions Progressive Disease (PD): either one of: * any new lesions * at least 20% relative and 5 mm absolute increase of SOD of target lesions compared to smallest SOD ever recorded for the patient Stable Disease (SD): not meeting criteria for PD or PR.

    Time frame: From the start of the study treatment until the end of treatment, an average of 6-8 months.

Secondary outcomes

  1. Incidence Proportion of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in the Second Line Setting

    The number of patients with any recorded adverse events (AE) defined as any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the trial. The incidence proportion or cumulative incidence is the percentage (%) of patients developing new AEs out of the total number at risk followed during that time frame.

    Time frame: 6-8 months, based on average length of treatment per patient

  2. Incidence of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in Performance Status 2 (PS2) Patients in Any Setting

    The number of patients whose Performance Status was equal to two at baseline, with any recorded adverse events (AE) defined as any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the trial. The incidence proportion or cumulative incidence is the percentage (%) of patients developing new AEs out of the total number at risk followed during that time frame.

    Time frame: 6-8 months (based on average length of treatment per patient)

Other outcomes

  1. Identification of Potential Genomic Biomarkers Predictive of Immune Response to Pembrolizumab

    This would be a retrospective analysis of blood samples collected for future research purposes only. Research bloods will be used to examine DNA and measure various blood biomarkers. These biomarkers may predict possible response to study treatment. As these samples are being taken before, during and after treatment, they will help us understand how the study treatments work. This will also enable us to learn whether or not the treatments have the desired effect, and to understand if these effects may be beneficial for the treatment of cancer of unknown primary (CUP). This information may also be used to develop and test other new treatments in the future. The panel of potential biomarkers against which the blood plasma will be tested has not been established yet. Information gained from this research component is not directly beneficial to patients taking part in this clinical trial.

    Time frame: 12 months (post study completion)

06

Results

Posted May 4, 2026
Limitations and caveats
1. Dissolution of the NCRI CUP Working Group affect sample acquisitions and engagement around NCRI CUP working infrastructure. 2. External factors in addition to the dissolution of the NCRI CUP working group and post-COVID research infrastructure challenges results in low sample size and limited number of negative controls (compared to 350 in previous ICI research) that made it difficult to filter out bacterial taxa associated with contamination, adversely affecting the exploratory analysis.

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab
Started35
Completed35
Not completed0

Outcome measures

PrimaryOverall Response Rate (ORR) by RECIST Criteria v1.1 in the Second-line & First-line Setting.

The Response Evaluation Criteria in Solid Tumours (RECIST) criteria v1.1. classifies response based on the assessment of target and non-target lesions on CT scans as: Complete Response (CR): requires all of: * disappearance of all target and non-target lesions * pathological lymph nodes must have reduced to \<10 mm in short axis * no new lesions Partial Response (PR): requires all of: * at least 30% decrease in sum of diameters (SOD) of target lesions compared to baseline sum diameters * non-progressive disease of non-target lesions * no new lesions Progressive Disease (PD): either one of: * any new lesions * at least 20% relative and 5 mm absolute increase of SOD of target lesions compared to smallest SOD ever recorded for the patient Stable Disease (SD): not meeting criteria for PD or PR.

Time frame:
From the start of the study treatment until the end of treatment, an average of 6-8 months.
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) by RECIST Criteria v1.1 in the Second-line & First-line Setting.
ParticipantsPembrolizumab
Complete Response (CR)0
Partial Response (PR)4
Stable Disease (SD)9
Progressive Disease (PD)13
Not Evaluable (NE)9
SecondaryIncidence Proportion of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in the Second Line Setting

The number of patients with any recorded adverse events (AE) defined as any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the trial. The incidence proportion or cumulative incidence is the percentage (%) of patients developing new AEs out of the total number at risk followed during that time frame.

Time frame:
6-8 months, based on average length of treatment per patient
Reported as:
Count of participants · Participants
Incidence Proportion of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in the Second Line Setting
ParticipantsPembrolizumab
Incidence Proportion of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in the Second Line Setting34
SecondaryIncidence of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in Performance Status 2 (PS2) Patients in Any Setting

The number of patients whose Performance Status was equal to two at baseline, with any recorded adverse events (AE) defined as any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the trial. The incidence proportion or cumulative incidence is the percentage (%) of patients developing new AEs out of the total number at risk followed during that time frame.

Time frame:
6-8 months (based on average length of treatment per patient)
Reported as:
Count of participants · Participants
Incidence of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in Performance Status 2 (PS2) Patients in Any Setting
ParticipantsPembrolizumab
Incidence of Adverse Events up to 8 Weeks After the Last Dose of Pembrolizumab in Performance Status 2 (PS2) Patients in Any Setting5
Other pre-specifiedIdentification of Potential Genomic Biomarkers Predictive of Immune Response to Pembrolizumab

This would be a retrospective analysis of blood samples collected for future research purposes only. Research bloods will be used to examine DNA and measure various blood biomarkers. These biomarkers may predict possible response to study treatment. As these samples are being taken before, during and after treatment, they will help us understand how the study treatments work. This will also enable us to learn whether or not the treatments have the desired effect, and to understand if these effects may be beneficial for the treatment of cancer of unknown primary (CUP). This information may also be used to develop and test other new treatments in the future. The panel of potential biomarkers against which the blood plasma will be tested has not been established yet. Information gained from this research component is not directly beneficial to patients taking part in this clinical trial.

Time frame:
12 months (post study completion)

Results for this outcome have not been posted.

Adverse events

Collected over From the start of the study treatment until the end of treatment, an average of 6-8 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab27/35 (77.1%)20/35 (57.1%)15/35 (42.9%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPembrolizumab
Alanine aminotransferase increasedInvestigations2/35
DiarrhoeaGastrointestinal disorders2/35
Abdominal painGastrointestinal disorders2/35
HyponatraemiaMetabolism and nutrition disorders1/35
ConfusionPsychiatric disorders1/35
Pericardial effusionCardiac disorders1/35
Peripheral swellingCardiac disorders1/35
HypoaesthesiaNervous system disorders1/35
Haemoglobin decreasedInvestigations1/35
Pleural effusionRespiratory, thoracic and mediastinal disorders1/35
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPembrolizumab
FatigueGeneral disorders14/35
Abdominal painGastrointestinal disorders9/35
ConstipationGastrointestinal disorders8/35
VomitingGastrointestinal disorders8/35
Decreased appetiteMetabolism and nutrition disorders6/35
HypothyroidismEndocrine disorders6/35
ArthralgiaMusculoskeletal and connective tissue disorders5/35
NauseaGastrointestinal disorders5/35
PyrexiaGeneral disorders5/35
DyspnoeaRespiratory, thoracic and mediastinal disorders4/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pembrolizumab
Median58 (50 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab
Female21
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab
Hispanic or Latino0
Not Hispanic or Latino33
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Pembrolizumab
United Kingdom35
Histology
Histology(Participants)Pembrolizumab
Poorly differentiated adenocarcinoma or carcinoma11
Well or Moderately Differentiated Adenocarcinoma9
Undifferentiated Adenocarcinoma or Carcinoma8
Squamous cell carcinoma7
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pembrolizumab
0 to 130
25
EORTC QLQ-C30 Summary Score
EORTC QLQ-C30 Summary Score(units on a scale)Pembrolizumab
Mean70 ± 18
07

Study locations

3 sites
  • Hammersmith Hospital - Imperial College Healthcare NHS Trust
    Hammersmith, London W12 0HS, United Kingdom
  • Gastrointestinal Units, The Royal Marsden NHS Foundation Trust (Sutton and Chelsea)
    Sutton, Surrey, United Kingdom
  • Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust
    London, United Kingdom
08

References and documents

Publications

  • Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012 Jul;23(7):1854-63. doi: 10.1093/annonc/mdr536. Epub 2011 Nov 24. PubMed 22115926 ↗
  • Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021 Mar 26;371(6536):eabc4552. doi: 10.1126/science.abc4552. PubMed 33766858 ↗
  • Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 May 29;368(6494):973-980. doi: 10.1126/science.aay9189. PubMed 32467386 ↗
  • Wasan H, Paul J, Nicolson MC, Evans TRJ, McMahon L, Morris A, McCartney E, Bridgewater C, Bowtell D, Erlander M, Oien KA. Clinical outcomes from the UK CUP-ONE Study: A Multi-centre trial to assess the efficacy of Epirubicin, Cisplatin and Capecitabine (ECX) in carcinomas of unknown primary (CUP) with prospective validation of molecular classifiers. Annals of Oncology 25 (Supplement 4): iv394-iv405, 2014. doi:10.1093/annonc/mdu345.8

Study documents

  • Study protocol · Dec 8, 2021
  • Statistical analysis plan · May 6, 2024
  • Informed consent form · Oct 15, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03752333
Lead sponsor
Imperial College London
Collaborators
Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Nov 26, 2018
Start date
Feb 22, 2019
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Results posted
May 4, 2026
Last update
May 4, 2026

Study contacts

Harpreet Wasan, MBBS, FRCP
principal investigator · Imperial College London
Sheela Rao, MBBS, FRCP
principal investigator · The Royal Marsden Hospitals, Sutton and Chelsea
Sarah Ngan, MBBS, FRCP
principal investigator · Guy's and St Thomas' NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms, Unknown Primary→

Other studies from this sponsor

Imperial College London

Start the discussion